// App-Quantinova.ai

: INTREPID study: Once-daily single-inhaler fluticasone furoate/umeclidinium/vilanterol vs multiple-inhaler triple therapy; sub-analysis by prior medication strata

Researchers

Presenter

  • Chris Compton

Principal Investigators

  • Sally Worsley

  • Dawn Midwinter

  • Afisi Ismaila

  • Kai-Michael Beeh

  • Valentina Di Boscio

  • Janwillem Kocks

  • Jose M. Marin

  • Maggie Tabberer

  • Neil G. Snowise

  • David M.G. Halpin

Medical Centers

  • GlaxoSmithKline, Brentford, Middlesex, United Kingdom

  • GlaxoSmithKline, Hertfordshire, United Kingdom.

  • GSK, Stockley Park West, Uxbridge, Middlesex, United Kingdom,

  • GlaxoSmithKline and McMaster University, Collegeville, PA (USA and Hamilton, ON (Canada, United States of America

  • Insaf Respiratory Research Institute, Wiesbaden, Germany,

  • General Practitioners Research Institute and University of Groningen, University Medical Center Groningen, GRIAC Research Institute and Observational and Pragmatic Research Institute, Groningen (Netherlands, Groningen (Netherlands and Singapore (Singapore, Netherlands

  • Hospital Miguel Servet, Zaragoza, Spain

  • GlaxoSmithKline (at the time of the study and King's College, Brentford, Middlesex and London, United Kingdom

  • University of Exeter Medical School, College of Medicine and Health, University of Exeter, Exeter, United Kingdom

Locations

  • United Kingdom

  • United States

  • Germany

  • Netherlands

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • fluticasone furoate/umeclidinium/vilanterol

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved